HomeCompareDNBBY vs JNJ

DNBBY vs JNJ: Dividend Comparison 2026

DNBBY yields 6.03% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DNBBY wins by $18121.33M in total portfolio value
10 years
DNBBY
DNBBY
● Live price
6.03%
Share price
$31.36
Annual div
$1.89
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18121.36M
Annual income
$17,561,586,027.00
Full DNBBY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — DNBBY vs JNJ

📍 DNBBY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDNBBYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DNBBY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DNBBY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DNBBY
Annual income on $10K today (after 15% tax)
$512.28/yr
After 10yr DRIP, annual income (after tax)
$14,927,348,122.95/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, DNBBY beats the other by $14,927,344,136.96/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DNBBY + JNJ for your $10,000?

DNBBY: 50%JNJ: 50%
100% JNJ50/50100% DNBBY
Portfolio after 10yr
$9060.70M
Annual income
$8,780,795,358.20/yr
Blended yield
96.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

DNBBY
Analyst Ratings
3
Buy
2
Hold
3
Sell
Consensus: Buy
Altman Z
-0.4
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DNBBY buys
1
JNJ buys
0
PoliticianChamberTickerTypeAmountDate
Daniel Goldman🏢 House$DNBBY▼ Sell$15,001 - $50,0002023-07-10
Daniel Goldman🏢 House$DNBBY▼ Sell$15,001 - $50,0002023-03-31
John Rutherford🏢 House$DNBBY▼ Sell$1,001 - $15,0002022-03-16
John Rutherford🏢 House$DNBBY▲ Buy$1,001 - $15,0002022-02-17
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDNBBYJNJ
Forward yield6.03%2.13%
Annual dividend / share$1.89$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$18121.36M$30.3K
Annual income after 10y$17,561,586,027.00$4,689.40
Total dividends collected$18082.58M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: DNBBY vs JNJ ($10,000, DRIP)

YearDNBBY PortfolioDNBBY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,905$1,205.36$10,592$272.30+$1.3KDNBBY
2$15,421$2,682.28$11,289$357.73+$4.1KDNBBY
3$22,995$6,494.13$12,123$472.89+$10.9KDNBBY
4$42,704$18,100.08$13,141$629.86+$29.6KDNBBY
5$108,524$62,830.78$14,408$846.81+$94.1KDNBBY
6$414,573$298,451.84$16,021$1,151.60+$398.6KDNBBY
7$2,574,645$2,131,051.88$18,122$1,588.22+$2.56MDNBBY
8$27,492,416$24,737,546.14$20,930$2,228.20+$27.47MDNBBY
9$523,156,985$493,740,099.16$24,792$3,191.91+$523.13MDNBBY
10$18,121,364,000$17,561,586,027.00$30,274$4,689.40+$18121.33MDNBBY

DNBBY vs JNJ: Complete Analysis 2026

DNBBYStock

DNB Bank ASA provides financial services for retail and corporate customers in Norway and internationally. The company offers personal banking products and services, including savings and investment products; loans, such as home mortgages, and car and consumer loans; pet, home and property, travel, and personal insurance products, as well as insurance products for vehicles; retirement savings products; foreign exchange and treasury activities; and Internet and mobile banking services, as well as cards. It also provides business banking products and services comprising savings and investment products consisting of savings accounts, fixed rate deposits, exchange traded products, bonds and commercial papers, asset management, and equity services; financing, such as installment loans, overdraft facility, bank guarantees, leasing, factoring, and trade and export financing services; transaction banking services; research, commodities, bonds and commercial papers, corporate finance, debt capital market, equities, foreign exchange and interest rates, and securities services; and Internet services, including online equity trading, online FX trading, e-confirmation, equities execution, and investor and margin accounts, as well as pension services. In addition, the company provides investment banking services, such as mergers and acquisition, and equity and debt capital market services; foreign exchange, interest rates, equities, commodities, fixed income, research, private equity, and securities services; and corporate banking services. Further, it offers private banking services. The company offers its products and services to various sectors, including energy; financial institutions; healthcare; manufacturing; packaging and forest products; seafood; shipping, offshore, and logistics; and telecom, media, and technology. DNB Bank ASA was founded in 1822 and is headquartered in Oslo, Norway.

Full DNBBY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this DNBBY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DNBBY vs SCHDDNBBY vs JEPIDNBBY vs ODNBBY vs KODNBBY vs MAINDNBBY vs ABBVDNBBY vs MRKDNBBY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.